Basic Information
| LncRNA/CircRNA Name | LINC-PINT |
| Synonyms | LINC-PINT, LincRNA-Pint, MKLN1-AS1, PINT |
| Region | GRCh38_7:130938963-131110176 |
| Ensemble | ENSG00000231721 |
| Refseq | NR_015431 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR, Western blot, RIP, RNAi, other |
| Sample | ccRCC tissues and cell lines (786-O, A498, 769P,Caki-2, Caki-1, ACHN, OS-RC-2, and SN12-PM6) |
| Expression Pattern | up-regulated |
| Function Description | Furthermore, we observed that the level of LINC-PINT depended on gender as well as on pT and TNM stage of patients with ccRCC. Moreover, patients with high LINC-PINT expression had poor disease-free survival and overall survival. Functionally, overexpression of LINC-PINT promoted ccRCC cell proliferation, induced cell cycle progression, and inhibited apoptosis. LINC-PINT was primarily located in cell nuclei and interacted with EZH2. When EZH2 was knocked down in 769P and OS-RC-2 cells overexpressing LINC-PINT, the effect of LINC-PINT on cell proliferation, cell cycle, and apoptosis was partially reversed. Additionally, inducing p53 by doxorubicin (Dox) promoted LINC-PINT expression. |
| Pubmed ID | 31417274 |
| Year | 2019 |
| Title | Long Noncoding RNA LINC-PINT Promotes Proliferation Through EZH2 and Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma |
External Links
| Links for LINC-PINT | GenBank HGNC NONCODE |
| Links for renal cell carcinoma | OMIM COSMIC |